Clinical Trials Can Be Scary – But with Advice From Past Participants, They Don’t Have To Be

Video

Clinical trials may seem scary and challenging for patients with cancer, but in reality, they don’t have to be. Here is how talking to former patients on clinical trials can help.

The idea of participating in a clinical trial can conjure up worries of untested treatment methods and unknown outcomes. But in reality, taking part in the research side of cancer treatment is a unique opportunity to “pay it forward”, according to Martha Raymond, the founder and CEO of The Raymond Foundation.

In an interview with CURE®, Raymond discussed how she and her colleagues at The Raymond Foundation work to connect patients who are on the fence about clinical trials with those who have “walked the walk” and find that those conversations tend to alleviate those fears and help make the decision to participate an easy one.

Transcription:

So, from so many individuals that, over the years, I've spoken to, and our team has spoken to individuals that have participated in a clinical trial or even two or three clinical trials. I know a couple of individuals that are going through trials right now, and maybe their second or third. I think the benefits and just the understanding that, yes, it is scary. And I think we have to acknowledge that, because it's a little bit of that fear of the unknown. And that makes total sense.

But I think for patients that begin a trial, they do feel that sense of like I am paying it forward, I am helping individuals that may come after me. And while, yes, this may be the perfect solution to the type of cancer I have, and it may work wonderfully and the trial may be a great success, they also have that added knowledge that they are paying it forward that they are helping individuals that will come after them. So I think, from talking to patients, that's one of the main things we hear that.

And then the other thing I think is so important is when an individual is possibly considering a trial, many times I will say, let me ask a patient currently under trial, if they'll speak with you for a moment. And I think anytime we're able to match somebody up, even if it's not the same disease state, or even if it's not the same trial, the new patient comes away like, “Okay, I get it now, and they've answered my questions because they've walked the walk.” And so, we always try, no matter how difficult it might be, to find an individual that's gone through a trial to match up with somebody considering a trial.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Image of a woman with brown shoulder-length hair in front of a gray background that says CURE.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Related Content